Hemispherian develops personalized cancer therapies to fight glioblastoma multiforme tumors, with the aim of significantly increasing life expectancy, improving patient comfort, and increasing overall survival rates for GBM patients. The company is focused on developing a drug to treat Glioblastoma Multiforme, an aggressive type of cancer, and provides physicians with access to novel drugs in areas of unmet medical needs.